M Siddiqi, the chairman of the Cancer Foundation of India in Kolkata, and R N Sharan, Professor of Biochemistry at North-Eastern Hill University, Shillong, have written to Health Minister J P Nadda regarding the issue.
"The Electronic Nicotine Delivery System (ENDS), which is more popularly known as electronic cigarette or e-cig, has emerged as a new generation NRT (nicotine replacement therapy). Systematically reviewing all the available literature on ENDS recently, one of us found that it may also offer an effective method of tobacco-smoking cessation," they said in the letter.
"We, believe that ENDS to become a promising alternative NRT, there is an immediate need of further research on its long-term health effects. Furthermore, regulation should be put in place for quality controls and limiting its sale to adults only.
"Finally, proof of compliance with safety and quality standards should be made mandatory for the manufacturers and retailers to ensure availability of safe products in the market," the letter said.
They brought forth the issue since a report on e-cigarette will be discussed at the ongoing 7th Conference of Parties (CoP7) of the World Health Organization's Framework Convention for Tobacco Control (WHO-FCTC), which India is hosting for the first time.
"India is strongly positioned to be a global leader in tobacco control by investing in research on smoking cessation approaches, and provide the rest of the world with a road map on tobacco control leadership.
"Currently, smoking cessation support in India is minimal with little or no efforts to develop proper communication strategy to achieve a significant decline in smoking population. On the other hand, a sound strategy in the Western world is showing positive results in terms of significant decline in tobacco-smoking," the letter said.
They said that cessation in the use of harmful tobacco products can be achieved in India with a combination of approaches since our country has huge diversity of cultures and traditions.
"Among NRTs, nicotine gums, patches, inhalators, etc. have been in use for a long time but the outcome has been very limited. Therefore, WHO is now recommending even chronic NRT usage," it added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
